List view / Grid view
26 June 2014 | By GlaxoSmithKline
GlaxoSmithKline plc announced the start of a Phase III study, SUPPORT (TRC112121), to evaluate the platelet supportive care effects of eltrombopag (Promacta™/Revolade™)...
25 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma...
24 June 2014 | By Myriad RBM
Myriad Genetics announced that Myriad RBM has entered into a research collaboration with Sanofi...
24 June 2014 | By Abbott
Abbott announced a definitive agreement to acquire Veropharm, a leading Russian pharmaceutical manufacturer...
23 June 2014 | By Novo Nordisk
New data from the phase 3a SCALE™ Diabetes trial were presented at the International Congress of Endocrinology and the Endocrine Society’s meeting, investigating the effect of liraglutide 3 mg in adults...
23 June 2014 | By Merck
MSD is commencing, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Idenix Pharmaceuticals, Inc...
19 June 2014 | By Sanofi
Sanofi announced that, in a pooled analysis, investigational therapy Toujeo® (insulin glargine [rDNA origin] injection, 300 U/mL) consistently showed significantly fewer low blood sugar events (hypoglycemia)...
19 June 2014 | By Johnson & Johnson
Janssen Pharmaceuticals, Inc. announced that it has entered into an exclusive license agreement with Vertex Pharmaceuticals for the worldwide development, manufacturing and commercialization of VX-787...
18 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
17 June 2014 | By Boehringer Ingelheim
Boehringer Ingelheim and Eli Lilly and Company presented results of two Phase III clinical trials studying the efficacy and safety of empagliflozin...
16 June 2014 | By Novo Nordisk
Data from a new phase 3 study demonstrated that once-daily Victoza® (liraglutide) provided greater glycaemic control versus placebo with no worsening of renal function in adults with type 2 diabetes and moderate renal impairment...
16 June 2014 | By Biogen Idec
Biogen Idec and AbbVie announced positive top-line results from the Phase 3 DECIDE clinical trial, designed to evaluate the superiority of once-monthly, subcutaneous daclizumab high-yield process...
16 June 2014 | By Oxford Global
After the continued success of the European Drug Discovery Summit Series, Oxford Global are pleased to announce the first Drug Discovery USA Congress...
12 June 2014 | By AstraZeneca
AstraZeneca announced a global licence agreement with Synairgen Plc for SNG001, a novel, inhaled interferon beta (IFN-beta) in clinical development for treating respiratory tract viral infections in patients with severe asthma...
12 June 2014 | By GlaxoSmithKline
ViiV Healthcare announced that they have entered into an agreement with Janssen R&D Ireland Ltd for the development and commercialisation of a single-tablet combining dolutegravir (Tivicay®) and Janssen’s non-nucleoside reverse transcriptase inhibitor rilpivirine (Edurant®1)...
